Sangamo Therapeutics (SGMO)
Market Price (6/18/2026): $0 | Market Cap: $-Sector: Health Care | Industry: Biotechnology
Sangamo Therapeutics (SGMO)
Market Price (6/18/2026): $0Market Cap: $-Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -101%, 3Y Excs Rtn is -152% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -110 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -319% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -46%, Rev Chg QQuarterly Revenue Change % is -78% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 22% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -261%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -262% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -155% High stock price volatilityVol 12M is 125% Key risksSGMO key risks include [1] a limited cash runway and a critical need for new funding or partnerships following the recent termination of its Pfizer collaboration, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -101%, 3Y Excs Rtn is -152% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -110 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -319% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -46%, Rev Chg QQuarterly Revenue Change % is -78% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 22% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -261%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -262% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -155% |
| High stock price volatilityVol 12M is 125% |
| Key risksSGMO key risks include [1] a limited cash runway and a critical need for new funding or partnerships following the recent termination of its Pfizer collaboration, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Sangamo Therapeutics (SGMO) stock has lost about 50% since 2/28/2026 because of the following key factors:
1. Nasdaq Delisting Due to Minimum Bid Price Non-Compliance.
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, for failing to meet the minimum $1.00 bid price requirement. Trading of its common stock on the Nasdaq Capital Market was suspended at the open of trading on May 5, 2026, and the stock subsequently began trading on the OTCQB Venture Market under the same symbol, SGMO. This transition to a lower-tier market signals significant financial distress and reduced market visibility.
2. Substantial Q1 2026 Earnings Miss and Revenue Decline.
On May 14, 2026, Sangamo reported its first-quarter 2026 financial results, revealing a significant underperformance. The company posted an Earnings Per Share (EPS) of -$0.08, missing the analyst forecast of -$0.06. Furthermore, reported revenue was $1.4 million, dramatically below the expected $35.43 million, marking a negative surprise of 96.05% and a sharp decline from $6.4 million in Q1 2025.
Show more
Sangamo Therapeutics (SGMO) stock has lost about 50% since 2/28/2026 because of the following key factors:
1. Nasdaq Delisting Due to Minimum Bid Price Non-Compliance.
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, for failing to meet the minimum $1.00 bid price requirement. Trading of its common stock on the Nasdaq Capital Market was suspended at the open of trading on May 5, 2026, and the stock subsequently began trading on the OTCQB Venture Market under the same symbol, SGMO. This transition to a lower-tier market signals significant financial distress and reduced market visibility.
2. Substantial Q1 2026 Earnings Miss and Revenue Decline.
On May 14, 2026, Sangamo reported its first-quarter 2026 financial results, revealing a significant underperformance. The company posted an Earnings Per Share (EPS) of -$0.08, missing the analyst forecast of -$0.06. Furthermore, reported revenue was $1.4 million, dramatically below the expected $35.43 million, marking a negative surprise of 96.05% and a sharp decline from $6.4 million in Q1 2025.
3. Critical Liquidity Concerns and Dependence on External Funding.
Sangamo Therapeutics is facing severe liquidity challenges, with cash and cash equivalents of $27.6 million as of March 31, 2026, projected to fund operations only into the third quarter of 2026. The company explicitly stated that the completion of its rolling Biologics License Application (BLA) submission for ST-920 in Fabry disease, a key pipeline asset, is "subject to our ability to secure adequate additional funding," highlighting a precarious financial position and reliance on securing additional capital or strategic partnerships.
Show less
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
2/28/2026 to 6/17/2026| Return | Correlation | |
|---|---|---|
| SGMO | -50.3% | |
| Market (SPY) | 8.3% | -3.7% |
| Sector (XLV) | -5.5% | 2.6% |
Fundamental Drivers
nullnull
Market Drivers
11/30/2025 to 6/17/2026| Return | Correlation | |
|---|---|---|
| SGMO | -53.4% | |
| Market (SPY) | 9.0% | 8.3% |
| Sector (XLV) | -3.6% | 7.8% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2025 to 6/17/2026| Return | Correlation | |
|---|---|---|
| SGMO | -53.8% | |
| Market (SPY) | 27.2% | 15.6% |
| Sector (XLV) | 15.6% | 11.7% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/17/2026| Return | Correlation | |
|---|---|---|
| SGMO | -80.8% | |
| Market (SPY) | 84.3% | 17.4% |
| Sector (XLV) | 23.9% | 18.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SGMO Return | -52% | -58% | -83% | 88% | -59% | -49% | -99% |
| Peers Return | -14% | -34% | 2% | -43% | 15% | -0% | -63% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| SGMO Win Rate | 33% | 25% | 42% | 58% | 33% | 33% | |
| Peers Win Rate | 37% | 45% | 45% | 38% | 52% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SGMO Max Drawdown | -57% | -65% | -92% | -77% | -72% | -80% | |
| Peers Max Drawdown | -57% | -54% | -49% | -64% | -62% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, NTLA, EDIT, RGNX, SRPT. See SGMO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/17/2026 (YTD)
How Low Can It Go
| Event | SGMO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -78.0% | -9.5% |
| % Gain to Breakeven | 354.4% | 10.5% |
| Time to Breakeven | 98 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.4% | -33.7% |
| % Gain to Breakeven | 47.9% | 50.9% |
| Time to Breakeven | 29 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.9% | -19.2% |
| % Gain to Breakeven | 61.1% | 23.8% |
| Time to Breakeven | 757 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -44.8% | -3.7% |
| % Gain to Breakeven | 81.1% | 3.9% |
| Time to Breakeven | 113 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -42.0% | -12.2% |
| % Gain to Breakeven | 72.3% | 13.9% |
| Time to Breakeven | 497 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -65.7% | -6.8% |
| % Gain to Breakeven | 191.2% | 7.3% |
| Time to Breakeven | 585 days | 15 days |
In The Past
Sangamo Therapeutics's stock fell -0.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SGMO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -78.0% | -9.5% |
| % Gain to Breakeven | 354.4% | 10.5% |
| Time to Breakeven | 98 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.4% | -33.7% |
| % Gain to Breakeven | 47.9% | 50.9% |
| Time to Breakeven | 29 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.9% | -19.2% |
| % Gain to Breakeven | 61.1% | 23.8% |
| Time to Breakeven | 757 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -44.8% | -3.7% |
| % Gain to Breakeven | 81.1% | 3.9% |
| Time to Breakeven | 113 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -42.0% | -12.2% |
| % Gain to Breakeven | 72.3% | 13.9% |
| Time to Breakeven | 497 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -65.7% | -6.8% |
| % Gain to Breakeven | 191.2% | 7.3% |
| Time to Breakeven | 585 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -22.6% | -0.2% |
| % Gain to Breakeven | 29.3% | 0.2% |
| Time to Breakeven | 16 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -50.6% | -17.9% |
| % Gain to Breakeven | 102.6% | 21.8% |
| Time to Breakeven | 343 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -44.7% | -15.4% |
| % Gain to Breakeven | 80.7% | 18.2% |
| Time to Breakeven | 169 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -85.6% | -53.4% |
| % Gain to Breakeven | 593.3% | 114.4% |
| Time to Breakeven | 1864 days | 1085 days |
In The Past
Sangamo Therapeutics's stock fell -0.9% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sangamo Therapeutics (SGMO)
Sangamo Therapeutics, Inc. (SGMO) is a clinical-stage biotechnology company dedicated to developing genomic medicines that aim to transform the lives of patients suffering from severe diseases. The company leverages a suite of platform technologies, including gene therapy, cell therapy, genome editing, and genome regulation, to achieve its therapeutic goals. At the core of Sangamo's innovation is its proprietary Zinc Finger Protein (ZFP) platform, which enables precise modification of DNA sequences through zinc finger nucleases and fine-tuning of gene expression using ZFP transcription factors.
The company's pipeline includes several key product candidates targeting a diverse range of conditions. Leading its development efforts is SB-525, a gene therapy currently in a Phase III clinical trial for hemophilia A. Other significant programs include ST-920, a gene therapy in Phase I/II trials for Fabry disease, and SAR445136, a cell therapy also in Phase I/II trials for sickle cell disease. Beyond these, Sangamo is exploring treatments for kidney transplant rejection, various cancers, and neurodegenerative disorders such as tauopathies and synucleinopathies, which include Parkinson's disease. Its development efforts are significantly bolstered by strategic collaborations and partnerships with major pharmaceutical companies like Pfizer, Sanofi, and Novartis.
Sangamo's primary customers are patients afflicted with inherited genetic disorders, certain types of cancer, and severe neurodegenerative diseases. The company also aims to serve patients requiring immune modulation in contexts like organ transplantation. By focusing on genomic medicines, Sangamo targets medical areas with high unmet needs, offering potential curative or significantly disease-modifying therapies to patient populations worldwide.
AI Analysis | Feedback
Sangamo is like Moderna, but instead of mRNA technology, they are developing a proprietary "zinc finger protein" (ZFP) platform to create advanced gene editing and cell therapies for a wide range of diseases.
Imagine Qualcomm as a foundational technology provider in the smartphone industry. Sangamo aims to be a similar foundational technology provider in genomic medicine, developing proprietary 'zinc finger protein' tools central to many cutting-edge gene and cell therapies, often in partnership with larger pharmaceutical companies.
AI Analysis | Feedback
- SB-525: A gene therapy in Phase III clinical trial for the treatment of hemophilia A.
- ST-920: A gene therapy in Phase I/II clinical trials for the treatment of Fabry disease.
- SAR445136: A cell therapy in Phase I/II clinical trials for the treatment of sickle cell disease.
- TX200: A chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection.
- KITE-037: A cell therapy developed for the treatment of cancer.
- ST-501: A therapy under development for the treatment of tauopathies.
- ST-502: A therapy under development for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease.
- Zinc Finger Protein (ZFP) Technology: A platform technology for modifying DNA sequences (nucleases) and regulating gene expression (transcription factors).
AI Analysis | Feedback
Sangamo Therapeutics (SGMO) is a clinical-stage biotechnology company that primarily operates through collaborative and strategic partnerships with larger pharmaceutical and biotechnology companies. These partnerships represent Sangamo's major customers, as these companies license Sangamo's technology platforms and drug candidates, providing funding through upfront payments, milestone payments, and royalties for further development and commercialization.
Based on the provided background, Sangamo Therapeutics' major customers (partners) include the following companies:
- Biogen Inc. (BIIB)
- Kite Pharma, Inc.
- Pfizer Inc. (PFE)
- Sanofi S.A. (SNY)
- Novartis AG (NVS)
- Shire International GmbH
- Dow AgroSciences LLC
- Sigma-Aldrich Corporation
- Genentech, Inc.
- Open Monoclonal Technology, Inc.
- F. Hoffmann-La Roche Ltd (RHHBY)
- Hoffmann-La Roche Inc. (RHHBY)
- California Institute for Regenerative Medicine
AI Analysis | Feedback
- Sigma-Aldrich Corporation
AI Analysis | Feedback
Sandy Macrae, Chief Executive Officer
Dr. Sandy Macrae has served as Sangamo's Chief Executive Officer and as a member of the Board of Directors since June 2016. He brings over twenty years of experience in the pharmaceutical industry. Before joining Sangamo, he was the Global Medical Officer of Takeda Pharmaceuticals from 2012 to March 2016, where he established and led the Global Medical Office. From 2001 to 2012, Dr. Macrae held various positions of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development, and Vice President, Business Development. Earlier in his career, he worked for SmithKline Beecham, focusing on clinical development in neurology and gastroenterology. Dr. Macrae earned his M.B., Ch.B. from Glasgow University and his Ph.D. in molecular genomics from King's College, Cambridge.
Nikunj Jain, Interim Chief Financial Officer
Nikunj Jain was appointed as Sangamo's interim Chief Financial Officer and principal financial officer in February 2026. He also holds the titles of Principal Accounting Officer and Vice President, Finance and Corporate Controller. Mr. Jain possesses extensive experience in finance, which is expected to support Sangamo's strategic objectives and financial oversight.
D. Mark McClung, Executive Vice President and Chief Operating Officer
D. Mark McClung was appointed Executive Vice President and Chief Business Officer in April 2020, and then assumed the role of Chief Operating Officer in November 2021, while continuing his Chief Business Officer responsibilities. In this capacity, he oversees commercial strategic planning, corporate and business development, product strategy and planning, and alliance management. Prior to Sangamo, Mr. McClung served as Vice President and General Manager of Global Oncology Commercial at Amgen from 2015 to 2019, and as Chief Commercial Officer at Onyx Pharmaceuticals. He began his pharmaceutical industry career at GlaxoSmithKline, where he held various leadership roles, including Vice President and Head of Global Commercial for GSK Oncology.
Nathalie Dubois-Stringfellow, Chief Development Officer
Dr. Nathalie Dubois-Stringfellow serves as the Chief Development Officer at Sangamo Therapeutics.
Gregory Davis, Head of Research and Technology
Dr. Gregory Davis is the Head of Research and Technology at Sangamo Therapeutics.
AI Analysis | Feedback
The key risks to Sangamo Therapeutics (SGMO) include:
- Clinical Development and Regulatory Approval Risk: As a clinical-stage biotechnology company, Sangamo's success is critically dependent on the successful completion of clinical trials for its pipeline candidates (e.g., SB-525 for hemophilia A, ST-920 for Fabry disease, SAR445136 for sickle cell disease, TX200 for kidney transplant rejection) and subsequent regulatory approvals. The failure of any of these programs in clinical trials, or the inability to obtain necessary regulatory approvals, would significantly impact the company's future prospects and financial viability.
- Reliance on Strategic Partnerships: Sangamo Therapeutics has numerous collaborative and strategic partnerships with major pharmaceutical and biotech companies, including Biogen MA, Inc., Kite Pharma, Inc., Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche Ltd, among others. A significant portion of the company's research, development, and potential commercialization efforts rely on these collaborations. The termination of these partnerships, failure of partners to meet their obligations, or adverse changes in collaboration terms could materially impact Sangamo's ability to advance its pipeline and generate revenue.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable markets for Sangamo Therapeutics' main products and services are outlined below, with market sizes provided for the specified regions.
Hemophilia A (SB-525)
The global hemophilia A market was estimated at approximately USD 14.11 billion in 2024 and is projected to reach USD 21.07 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.91% from 2025 to 2030. Another estimate places the global market value at US$ 10,288.7 million in 2023, with a projection to reach US$ 28,447.2 million by 2034, exhibiting a CAGR of 9.69%. The market across the 7 major markets (7MM), which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was USD 12.2 billion in 2024, and is projected to reach USD 16.756 billion by 2034. In 2024, the United States accounted for approximately USD 5.920 billion of this market.
Fabry Disease (ST-920)
The global Fabry disease treatment market size was estimated at USD 2.54 billion in 2023 and is projected to reach USD 4.93 billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. Other reports indicate the global market size was USD 2.45 billion in 2025 and is predicted to increase to approximately USD 5.20 billion by 2035, at a CAGR of 7.82%. The Fabry disease therapeutics market in the 7MM was approximately USD 1,700 million in 2024. The United States contributed the highest market share in the 7MM, with approximately USD 880 million in 2024.
Sickle Cell Disease (SAR445136)
The global sickle cell disease treatment market size was estimated at USD 2.758.5 million in 2023 and is projected to reach USD 7.422.4 million by 2030, with a CAGR of 15.7% from 2024 to 2030. Another estimate puts the global market size at USD 2.79 billion in 2023, projected to reach USD 7.52 billion by 2031 at a CAGR of 13.21%. More recent data suggests the global market size was USD 3.94 billion in 2025 and is projected to reach USD 20.47 billion by 2034, growing at a CAGR of 20.10% from 2026 to 2034. In 2023, the United States accounted for approximately USD 603 million of the market within the 6MM (United States, France, Germany, Italy, Spain, and the United Kingdom).
HLA-A2 Mismatched Kidney Transplant Rejection (TX200)
While a specific market size for "HLA-A2 mismatched kidney transplant rejection" is not readily available, the broader global kidney transplant rejection market provides an indication of the addressable market. This market is projected to grow from USD 2.8 billion in 2024 to nearly USD 4.5 billion by 2030, reflecting a CAGR of 8.3% over the forecast period. The kidney transplant rejection market across the 7MM was valued at approximately USD 3.97 billion in 2023 and is projected to increase from USD 4.260 million in 2025 to USD 6.647 million in 2034, with a CAGR of 5.07%. The United States alone held approximately USD 2.448 million of this market in 2023.
Cancer (KITE-037 - Cell Therapy)
The global oncology cell therapy market is projected to generate sales of around USD 25 billion by 2031, growing at a CAGR of 24.5%. The global cell therapy market as a whole was estimated to be USD 8.88 billion in 2025 and is projected to grow from USD 12.34 billion in 2026 to USD 190.36 billion by 2034, exhibiting a CAGR of 40.78%. The oncology segment captured the largest cell therapy market share in 2024 and is anticipated to dominate with a 100.0% share in 2025. Specifically, the global CAR T-cell therapy market size was calculated at USD 5,206.15 million in 2025 and is predicted to increase to approximately USD 23,247.29 million by 2034, expanding at a CAGR of 18.10%.
Tauopathies (ST-501)
The global tauopathies treatment market was estimated at USD 1,144.7 million in 2025 and is expected to reach USD 2,230.7 million in 2032, exhibiting a CAGR of 10.0% from 2025 to 2032. Another report states the global market size was approximately USD 1.5 billion in 2023 and is projected to reach approximately USD 2.7 billion by 2032, reflecting a CAGR of 6.7%. For the 7MM, the tauopathies market reached a value of USD 712.4 million in 2024 and is expected to reach USD 1,620.0 million by 2035, exhibiting a CAGR of 7.76%.
Synucleinopathies (ST-502)
For synucleinopathies, which include Parkinson's disease and other related conditions, the market across the 7MM (United States, EU4, United Kingdom, and Japan) reached a value of USD 692.9 million in 2024 and is expected to reach USD 1,148.9 million by 2035, exhibiting a growth rate (CAGR) of 4.71%. The global alpha synuclein market (relevant for synucleinopathies) was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.8 billion by 2032, growing at a CAGR of 9.5%.
Parkinson's Disease (a type of synucleinopathy)
The global Parkinson's disease therapeutics market was valued at USD 6.2 billion in 2024 and is set to reach USD 13.3 billion by 2034, growing at a CAGR of 8.1% from 2025 to 2034. The Parkinson's disease diagnosis and treatment market is expected to increase from USD 7.49 billion in 2025 to USD 17.57 billion by 2035, growing at a CAGR of 8.9%. In the US, the Parkinson's disease market was approximately USD 1,883 million in 2023.
Neuromuscular Disease (broader category including synucleinopathies)
The global neuromuscular disease therapeutics market size is estimated to grow by USD 13.73 billion, at a CAGR of 14.6% between 2024 and 2029. Another source indicates that the global neuromuscular disease therapeutics market will grow from USD 13.70 billion in 2024 to USD 45.62 billion by 2033, at a CAGR of 14.4% from 2025 to 2033.
AI Analysis | Feedback
Sangamo Therapeutics (SGMO) is poised for potential revenue growth over the next 2-3 years, driven primarily by the advancement of its genomic medicine pipeline and strategic collaborations. The company's focus on its proprietary zinc finger technology and capsid discovery platforms underpins these efforts.
Here are 3-5 expected drivers of future revenue growth:
- Commercialization of ST-920 for Fabry Disease: Sangamo's gene therapy for Fabry disease, ST-920, is a leading candidate for near-term revenue generation. The company is actively pursuing an accelerated approval pathway with the U.S. FDA, supported by positive clinical data demonstrating a positive mean annualized eGFR slope at 52 weeks across all treated patients. A Biologics License Application (BLA) submission is anticipated as early as the first quarter of 2026. Patient support and interest from potential partners are also strong, which bodes well for a successful launch if approved.
- Advancement of Neurological Gene Therapies: Sangamo is increasingly concentrating its efforts on developing genomic medicines for neurological disorders. Key programs in this area include ST-503 for chronic neuropathic pain, which has entered patient enrollment, and ST-506 for prion disease, which has shown compelling preclinical data with plans for a Clinical Trial Application (CTA) submission in mid-2026. The expansion and progression of these neurology programs, along with others for tauopathies and synucleinopathies, could provide significant future revenue streams.
- Strategic Partnerships and Collaborations: Ongoing and new collaborations are crucial for Sangamo's revenue growth, providing non-dilutive capital and potential licensing agreements. The company has a history of strategic alliances with major pharmaceutical companies, including a partnership for its Fabry disease program. Further monetization of its platforms and pipeline through such partnerships will be a key driver.
- Leveraging Proprietary Zinc Finger and Capsid Discovery Platforms: Sangamo's core zinc finger protein (ZFP) and capsid discovery platforms are foundational to its genomic medicine approach. These technologies enable the development of new gene and cell therapies, as well as genome editing and regulation treatments, particularly for challenging neurological indications. The successful application of these platforms to generate and advance a robust pipeline of novel therapies will drive long-term revenue growth through new product launches and collaborations.
AI Analysis | Feedback
Share Issuance
- Sangamo Therapeutics' shares outstanding have significantly increased, growing by 78.1% in the past year, from approximately 140 million in 2021 to over 304 million by late 2025 and early 2026.
- In May 2025, the company announced the pricing of a $23 million underwritten registered direct equity offering.
- In February 2026, Sangamo Therapeutics announced the pricing of a $25.0 million underwritten offering of its common stock and pre-funded warrants.
Inbound Investments
- In August 2024, Sangamo entered into a licensing agreement with Genentech, including $50 million in near-term upfront license fees and milestone payments, with potential for up to $1.9 billion in development and commercial milestone payments.
- The company secured a capsid license agreement with Astellas in December 2024, which included a $20 million upfront payment and eligibility for up to $1.3 billion in additional milestone payments.
- In May 2025, Sangamo received an $18 million upfront license fee from Eli Lilly and Company for a capsid license agreement for central nervous system disease targets, with potential for up to $1.4 billion in additional milestone payments.
Capital Expenditures
- In the most recent quarter, capital expenditures totaled approximately $64,000.
- Over the last 12 months, capital expenditures were approximately $240,000.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.20 |
| Mkt Cap | 1.1 |
| Rev LTM | 52 |
| Op Inc LTM | -184 |
| FCF LTM | -189 |
| FCF 3Y Avg | -238 |
| CFO LTM | -187 |
| CFO 3Y Avg | -229 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -23.1% |
| Rev Chg 3Y Avg | 21.8% |
| Rev Chg Q | -39.2% |
| QoQ Delta Rev Chg LTM | -4.5% |
| Op Inc Chg LTM | -7.0% |
| Op Inc Chg 3Y Avg | -4.8% |
| Op Mgn LTM | -305.8% |
| Op Mgn 3Y Avg | -469.3% |
| QoQ Delta Op Mgn LTM | 15.1% |
| CFO/Rev LTM | -314.7% |
| CFO/Rev 3Y Avg | -431.8% |
| FCF/Rev LTM | -316.9% |
| FCF/Rev 3Y Avg | -446.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.1 |
| P/S | 5.6 |
| P/Op Inc | -2.2 |
| P/EBIT | -2.0 |
| P/E | -1.9 |
| P/CFO | -1.8 |
| Total Yield | -32.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -31.6% |
| D/E | 0.2 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 14.6% |
| 3M Rtn | 3.7% |
| 6M Rtn | -11.4% |
| 12M Rtn | 5.2% |
| 3Y Rtn | -68.6% |
| 1M Excs Rtn | 14.3% |
| 3M Excs Rtn | -8.3% |
| 6M Excs Rtn | -22.3% |
| 12M Excs Rtn | -20.8% |
| 3Y Excs Rtn | -140.7% |
Comparison Analyses
Price Behavior
| Market Price | $0.21 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 04/06/2000 | |
| Distance from 52W High | -70.9% | |
| 50 Days | 200 Days | |
| DMA Price | $0.27 | $0.45 |
| DMA Trend | down | down |
| Distance from DMA | -21.0% | -51.7% |
| 3M | 1YR | |
| Volatility | 214.3% | 129.4% |
| Downside Capture | 287.29 | 312.03 |
| Upside Capture | -90.23 | 119.50 |
| Correlation (SPY) | -7.0% | 14.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -3.21 | -1.48 | -0.40 | 1.10 | 1.66 | 1.55 |
| Up Beta | -5.78 | -3.62 | -5.60 | -2.89 | -0.62 | 1.14 |
| Down Beta | -1.50 | -9.75 | 0.46 | 2.66 | 2.56 | 0.80 |
| Up Capture | 325% | 18% | -25% | 95% | 152% | 647% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 6 | 14 | 21 | 48 | 100 | 327 |
| Down Capture | -1598% | 336% | 290% | 250% | 191% | 114% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 1 | 14 | 28 | 61 | 132 | 397 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGMO | |
|---|---|---|---|---|
| SGMO | -72.9% | 126.0% | -0.55 | - |
| Sector ETF (XLV) | 13.1% | 15.1% | 0.61 | 11.2% |
| Equity (SPY) | 24.5% | 12.4% | 1.48 | 15.7% |
| Gold (GLD) | 24.7% | 27.5% | 0.79 | -8.5% |
| Commodities (DBC) | 22.7% | 18.9% | 0.95 | -4.7% |
| Real Estate (VNQ) | 10.6% | 13.8% | 0.49 | 10.4% |
| Bitcoin (BTCUSD) | -38.7% | 42.4% | -1.04 | 14.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGMO | |
|---|---|---|---|---|
| SGMO | -59.0% | 112.3% | -0.27 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 22.0% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 24.2% |
| Gold (GLD) | 16.9% | 18.3% | 0.75 | -0.3% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | -0.1% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 23.0% |
| Bitcoin (BTCUSD) | 12.3% | 54.2% | 0.42 | 15.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGMO | |
|---|---|---|---|---|
| SGMO | -32.6% | 98.1% | 0.06 | - |
| Sector ETF (XLV) | 9.5% | 16.6% | 0.46 | 26.1% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 26.5% |
| Gold (GLD) | 12.4% | 16.1% | 0.63 | -0.6% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 4.9% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 19.6% |
| Bitcoin (BTCUSD) | 60.4% | 66.8% | 1.00 | 12.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/17/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | 0.0% | 9.5% | 60.2% |
| 11/6/2025 | -16.3% | -14.6% | -8.4% |
| 8/7/2025 | -5.3% | 11.9% | 8.8% |
| 3/17/2025 | -16.2% | -13.9% | -26.9% |
| 11/12/2024 | -10.0% | -27.7% | -29.5% |
| 8/6/2024 | -13.5% | -1.5% | -24.1% |
| 5/9/2024 | 7.3% | 16.3% | 10.4% |
| 3/13/2024 | -8.8% | -10.6% | -36.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 6 |
| # Negative | 14 | 14 | 16 |
| Median Positive | 2.6% | 10.0% | 9.6% |
| Median Negative | -9.4% | -11.0% | -16.0% |
| Max Positive | 19.1% | 22.0% | 60.2% |
| Max Negative | -22.1% | -35.7% | -41.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | 0.0% | 9.5% | 60.2% |
| 11/6/2025 | -16.3% | -14.6% | -8.4% |
| 8/7/2025 | -5.3% | 11.9% | 8.8% |
| 3/17/2025 | -16.2% | -13.9% | -26.9% |
| 11/12/2024 | -10.0% | -27.7% | -29.5% |
| 8/6/2024 | -13.5% | -1.5% | -24.1% |
| 5/9/2024 | 7.3% | 16.3% | 10.4% |
| 3/13/2024 | -8.8% | -10.6% | -36.7% |
| 11/1/2023 | -22.1% | -35.7% | -23.1% |
| 8/8/2023 | -7.9% | -11.4% | -16.5% |
| 4/26/2023 | -0.6% | -17.4% | -17.4% |
| 2/22/2023 | 0.3% | 1.4% | -41.6% |
| 11/3/2022 | -12.8% | -3.9% | -14.7% |
| 8/4/2022 | 9.0% | 22.0% | 15.9% |
| 5/5/2022 | -3.7% | -12.1% | -14.0% |
| 2/24/2022 | 3.3% | -1.6% | 0.7% |
| 11/4/2021 | 19.1% | 10.5% | -11.4% |
| 8/5/2021 | -2.1% | 2.4% | 1.1% |
| 5/4/2021 | -8.5% | -6.2% | -5.2% |
| 2/24/2021 | -10.6% | -10.5% | -2.0% |
| 11/4/2020 | 1.4% | -5.1% | -15.5% |
| 8/5/2020 | 1.9% | 1.6% | -12.3% |
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 6 |
| # Negative | 14 | 14 | 16 |
| Median Positive | 2.6% | 10.0% | 9.6% |
| Median Negative | -9.4% | -11.0% | -16.0% |
| Max Positive | 19.1% | 22.0% | 60.2% |
| Max Negative | -22.1% | -35.7% | -41.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/04/2021 | 10-Q |
| 12/31/2020 | 02/24/2021 | 10-K |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/05/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 02/28/2020 | 10-K |
| 09/30/2019 | 11/06/2019 | 10-Q |
| 06/30/2019 | 08/07/2019 | 10-Q |
Recent Forward Guidance
Updated 6/3/2026Latest: Q1 2026 Earnings Reported 5/14/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Operating Expenses (GAAP) | 110.00 Mil | 120.00 Mil | 130.00 Mil | -17.2% | Lower New | Guidance: 145.00 Mil for 2025 | |
| 2026 Total Operating Expenses (Non-GAAP) | 100.00 Mil | 110.00 Mil | 120.00 Mil | -18.5% | Lower New | Guidance: 135.00 Mil for 2025 | |
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Total Operating Expenses | 135.00 Mil | 145.00 Mil | 155.00 Mil | 0 | Affirmed | Guidance: 145.00 Mil for 2025 | |
| 2025 Non-GAAP Total Operating Expenses | 125.00 Mil | 135.00 Mil | 145.00 Mil | 0 | Affirmed | Guidance: 135.00 Mil for 2025 | |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.